相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1972
已完成
4
80.0%
Unknown
1
20.0%
暂无批准数据
- A Wistar Institute study published in Nature Aging identifies fructose as a signaling molecule that promotes ovarian cancer spread after chemotherapy. - Chemotherapy-surviving cells release fructose, which suppresses cholesterol in neighboring cells, reducing cellular adhesion and enabling metastasis. - Even without chemotherapy, high dietary fructose intake—such as from sugary drinks—can signal cancer cells to spread, suggesting nutrition may influence cancer progression. - The cholesterol-lowering mechanism raises questions about potential interactions between statins and chemotherapy, particularly in postmenopausal ovarian cancer patients.
- Scientists at The Wistar Institute developed an HIV vaccine candidate called WIN332 that induces neutralizing antibodies after a single immunization in nonhuman primates, achieving something never before observed in HIV vaccine research. - The innovative approach challenges conventional wisdom by removing the N332-glycan sugar molecule from the HIV envelope protein's V3-glycan epitope, contrary to previous vaccine design strategies. - A single injection of WIN332 induced detectable neutralization against HIV within three weeks, with significantly increased neutralization levels after a second booster injection. - This breakthrough could potentially reduce HIV vaccination protocols from seven to ten injections down to just three, making vaccines more accessible and affordable worldwide.
- The World Health Organization's International Nonproprietary Names Expert Committee approved "liraltagene autoleucel" as the official name for Anixa Biosciences' FSHR-targeted CAR-T therapy for recurrent ovarian cancer. - The therapy represents a novel CER-T (chimeric endocrine receptor-T cell) technology that uses the natural FSH ligand instead of antibody fragments to target the FSHR receptor on tumor cells. - Anixa is currently conducting a Phase 1 first-in-human trial in partnership with Moffitt Cancer Center, with plans to commence the 5th dose cohort in the coming weeks. - The INN approval marks a significant regulatory milestone toward potential global commercialization of this innovative immunotherapy approach for ovarian cancer treatment.
- INOVIO's Phase 1 trial demonstrated that DNA-encoded monoclonal antibodies (DMAbs) achieved sustained expression in all 39 participants through 72 weeks of follow-up, with peak serum concentrations reaching 1.61 μg/mL. - The synthetic DNA technology enabled in vivo production of monoclonal antibodies directly from muscle cells using intramuscular injection and electroporation delivery, avoiding viral vectors and lipid nanoparticles. - No anti-drug antibodies were detected in approximately 1,000 blood samples, addressing a key limitation of other gene-based delivery platforms while maintaining excellent safety profile. - Results published in Nature Medicine confirm the expressed antibodies successfully bound SARS-CoV-2 spike protein and neutralized pseudovirus in all tested participants.
- The Wistar Institute received a five-year, $17 million NIH grant to launch the iCure Consortium, developing individualized cure regimens for HIV through personalized medicine approaches. - The innovative six-part therapy combines neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and NK cells, and precision latency drugs tailored to each patient's unique virus. - The consortium aims to eliminate persistent viral reservoirs that remain after antiretroviral therapy, targeting durable drug-free remission for HIV patients. - Led by Nobel Laureate Drew Weissman and Luis Montaner, the initiative represents the first comprehensive personalized approach to HIV cure research.
- Researchers at The Wistar Institute discovered that FDA-approved PARP1 inhibitors can effectively halt Epstein-Barr virus-driven lymphoma growth through a novel mechanism. - The PARP inhibitor talazoparib demonstrated an 80% reduction in tumor growth in mouse models without causing typical DNA damage. - The drug works by disrupting the interaction between viral protein EBNA2 and oncogene MYC, blocking the virus's ability to activate cancer-promoting genes. - This repurposing approach could accelerate clinical application since PARP inhibitors already have established safety profiles for other cancer treatments.
- Scientists at The Wistar Institute, University of Pennsylvania, and INOVIO have successfully combined plasmid DNA with lipid nanoparticle delivery systems, overcoming previous stability and efficacy challenges. - The novel DNA-LNP formulation demonstrated robust, long-lasting immune responses in animal models, with memory responses persisting beyond one year after a single immunization. - In a critical test, a single dose of SARS-CoV-2 spike DNA-LNP vaccine provided complete protection against morbidity and mortality in a live virus challenge model, highlighting its potential as a next-generation vaccination platform.
- INOVIO's Phase 1 trial demonstrates DNA-encoded monoclonal antibodies (DMAbs) maintained stable levels for 72 weeks in all participants, potentially overcoming the short half-life limitations of traditional antibody therapies. - The study showed no anti-drug antibody formation across approximately 1,000 blood samples, a significant advantage over other gene-based delivery approaches where immune rejection has been problematic. - Researchers believe this breakthrough technology could transform treatment approaches for infectious diseases, cancer, and metabolic disorders by enabling sustained therapeutic protein delivery without requiring repeated administration.
